Accelerating translational research through Cardiff University’s Clinical Innovation pipeline
Lead Research Organisation:
Cardiff University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Barini E
(2018)
The Anthelmintic Drug Niclosamide and Its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1.
in Chembiochem : a European journal of chemical biology
Germuska M
(2019)
Dual-calibrated fMRI measurement of absolute cerebral metabolic rate of oxygen consumption and effective oxygen diffusivity
in NeuroImage
Lambourne O
(2022)
Inhibition of Ubiquitin Phosphorylation by Nucleoside Analogues
Lambourne OA
(2018)
Chemical Strategies for Activating PINK1, a Protein Kinase Mutated in Parkinson's Disease.
in Chembiochem : a European journal of chemical biology
Moses RL
(2020)
Novel epoxy-tiglianes stimulate skin keratinocyte wound healing responses and re-epithelialization via protein kinase C activation.
in Biochemical pharmacology
Pullin R
(2017)
Feasibility of detecting orthopaedic screw overtightening using acoustic emission.
in Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine
Vlahava VM
(2021)
Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus.
in The Journal of clinical investigation
Wright ME
(2018)
Can Blood Oxygenation Level Dependent Functional Magnetic Resonance Imaging Be Used Accurately to Compare Older and Younger Populations? A Mini Literature Review.
in Frontiers in aging neuroscience
| Description | (CaSR Biomedicine) - Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases |
| Amount | € 3,657,194 (EUR) |
| Funding ID | 675228 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 03/2016 |
| End | 02/2020 |
| Description | Contact angle goniometer and quartz crystal microbalance |
| Amount | £48,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2018 |
| End | 03/2019 |
| Description | Evaluate CMV targets with the aim of producing antibodies of therapeutic value against CMV infection |
| Amount | £180,000 (GBP) |
| Organisation | Kymab |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2019 |
| Description | Exploiting bacterial virulence to trigger antimicrobial release from orthopaedic implants |
| Amount | £264,216 (GBP) |
| Funding ID | EP/T016124/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 02/2022 |
| Description | Life Sciences Bridging Fund - Pathfinder |
| Amount | £50,672 (GBP) |
| Organisation | Welsh Assembly |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 12/2017 |
| Description | The role of antibody in enabling cell mediated control of HCMV-infection |
| Amount | £610 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2021 |
| Description | Wellcome Trust ISSF |
| Amount | £50,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 03/2019 |
| Description | Wellcome Trust ISSF |
| Amount | £50,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 03/2019 |
| Description | AP Densply |
| Organisation | Dentsply Sirona |
| Country | United States |
| Sector | Private |
| PI Contribution | Technology scoping |
| Collaborator Contribution | Technology scoping |
| Impact | Prospective bid to EPSRC |
| Start Year | 2018 |
| Description | AP QuayPharma |
| Organisation | QuayPharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Technology scoping |
| Collaborator Contribution | Technology scoping |
| Impact | Prospective collaborative bid for EPSRC funding |
| Start Year | 2018 |
| Description | University of Melbourne: School of Dentistry and School of Medicine Antimicrobial composite gels to prevent infection triggered failure of dental restorations |
| Organisation | University of Melbourne |
| Department | Faculty of Medicine, Dentistry & Health Sciences |
| Country | Australia |
| Sector | Academic/University |
| PI Contribution | Technology development. |
| Collaborator Contribution | Technology development when collaborator was at Cardiff Uni. International collaborations are new, so no contribution yet since they moved. |
| Impact | Funding for one PhD student funded by NICHR, and one PDRA post funded by MRC CiC. |
| Start Year | 2012 |
| Description | WA Heraeus |
| Organisation | Heraeus |
| Country | Germany |
| Sector | Private |
| PI Contribution | Liposomal antibiotic development |
| Collaborator Contribution | Biomechanical properties of bone cement |
| Impact | n/a |
| Start Year | 2017 |
| Description | WA Zimmer Biomet |
| Organisation | Zimmer Biomet |
| Country | United States |
| Sector | Private |
| PI Contribution | Technical scoping of liposomal antibiotics |
| Collaborator Contribution | Technical scoping of bone cement |
| Impact | n/a |
| Start Year | 2017 |
| Title | ANTI-VIRAL THERAPEUTIC |
| Description | The invention relates to an anti-viral composition comprising at least one, and ideally a plurality of, monoclonal antibodies, or fragments thereof; an immunogenic agent, vaccine or pharmaceutical composition comprising the afore anti-viral composition; said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition for use in the treatment of or prevention of a viral infection; use of said anti-viral composition in the manufacture of a medicament to treat or prevent a viral infection; a combination therapeutic for use in the treatment or prevention of a viral infection comprising said anti-viral composition, immunogenic agent, vaccine or pharmaceutical composition in combination with at least one other therapeutic agent; and a method of treating or preventing a viral infection comprising administering said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition to an individual having, or suspected of having, a viral infection. |
| IP Reference | WO2022162370 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | N/A |
| Title | Anti-viral Therapeutic |
| Description | anti-viral composition comprising at least one, and ideally a plurality of, monoclonal antibodies, or fragments thereof; an immunogenic agent, 5 vaccine or pharmaceutical composition comprising the afore anti-viral composition; said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition for use in the treatment of or prevention of a viral infection |
| IP Reference | GB2101066.5 |
| Protection | Patent application published |
| Year Protection Granted | 2021 |
| Licensed | Commercial In Confidence |
| Impact | n/a |
| Title | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HCMV |
| Description | Provided herein are compositions and methods for the treatment of HCMV infection in a subject. |
| IP Reference | WO2015073788 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | License in negotiation |
| Title | NEUROPROTECTIVE PEPTIDE |
| Description | The invention relates to inhibitors of MAPK3(ERK1 MAP kinase), in particular to polypeptides having the ability to stimulate the global ERK signalling pathway in the brain and their use as neuroprotective and/or cognitive enhancing agents.The invention also concerns related polynucleotides, vectors, host cells and pharmaceutical compositions able to inhibit MAPK3, causing the stimulation of the global ERK signalling pathway.Additionally, use of the afore inhibitors or stimulators in the treatment of neurodegenerative or neuropsychiatric disorders and cognitive impairment is also disclosed. |
| IP Reference | WO2019102201 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | Discussions with industry |